Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

You may also like

15 December 2015

OneVentures commits $3M to launch Australian wearable technology innovation for global dementia market

10 October 2021

Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson

26 August 2014

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Awards, Media Release

19 April 2016

Icon Group signs up Charm Health to support cancer care

13 August 2018

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

05 August 2018

Australian First:-Israeli venture partnership launches new Venture Credit Fund to invest in high-growth technology companies

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor